Skinvisible (SKVI) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.12 Bn | 626.36 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 440.93 Bn | 434.36 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 364.34 Bn | 357.20 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 268.31 Bn | 260.62 Bn | 11.24 Bn | 12.12% |
| 5 | Pfizer | 158.49 Bn | 146.79 Bn | 10.94 Bn | -28.09% |
| 6 | Sanofi | 52.52 Bn | 45.14 Bn | 10.79 Bn | -36.57% |
| 7 | Revolution Medicines | 44.27 Bn | 44.27 Bn | - | - |
| 8 | Incyte | 25.01 Bn | 20.47 Bn | 1.57 Bn | 42.23% |
| 9 | United Therapeutics | 21.18 Bn | 18.51 Bn | 683.80 Mn | 8.71% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 3.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.04% |
| Mar 31, 2026 | 43.92% |
| Dec 31, 2025 | 14.19% |
| Sep 30, 2025 | 15.74% |
| Jun 30, 2025 | -10.82% |
| Mar 31, 2025 | 8.69% |
| Dec 31, 2024 | 7.33% |
| Sep 30, 2024 | -12.91% |
| Jun 30, 2024 | -4.83% |
| Mar 31, 2024 | 12.64% |
| Dec 31, 2023 | -0.99% |
| Sep 30, 2023 | 11.14% |
| Jun 30, 2023 | 3.58% |
| Mar 31, 2023 | -52.16% |
| Dec 31, 2022 | 1.46% |
| Sep 30, 2022 | 1.81% |
| Jun 30, 2022 | 29.42% |
| Mar 31, 2022 | -1.97% |
| Dec 31, 2021 | -7.70% |
| Sep 30, 2021 | 39.39% |